Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Highlight articles
Nuclear medicine
Radiochemistry
Radiopharmaceutical Sciences
Radiopharmacy
Trends in radiopharmaceutical sciences
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
23 Mar 2023
23 Mar 2023
Historique:
received:
28
02
2023
accepted:
15
03
2023
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for
Sections du résumé
BACKGROUND
BACKGROUND
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
MAIN BODY
METHODS
This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.
CONCLUSION
CONCLUSIONS
Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for
Identifiants
pubmed: 36952073
doi: 10.1186/s41181-023-00192-5
pii: 10.1186/s41181-023-00192-5
pmc: PMC10036721
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6Informations de copyright
© 2023. The Author(s).
Références
Nature. 2022 Jun;606(7912):102-108
pubmed: 35344982
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
Q J Nucl Med Mol Imaging. 2010 Dec;54(6):629-38
pubmed: 21221070
Cancer Imaging. 2022 Dec 19;22(1):70
pubmed: 36529738
EJNMMI Res. 2022 Sep 16;12(1):62
pubmed: 36114433
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046
pubmed: 32617641
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126
pubmed: 34625828
J Nucl Med. 2022 Oct;63(10):1459-1462
pubmed: 35589403
Chem Rev. 2023 Jan 11;123(1):105-229
pubmed: 36399832
Eur Urol. 2022 Nov;82(5):501-509
pubmed: 35690515
Antioxid Redox Signal. 2016 Sep 10;25(8):467-84
pubmed: 27224059
EJNMMI Radiopharm Chem. 2022 Dec 2;7(1):31
pubmed: 36459299
Nat Chem. 2022 Dec;14(12):1367-1374
pubmed: 36344821
J Nucl Med. 2022 Dec;63(12):1859-1864
pubmed: 35772959
Leukemia. 2022 Jun;36(6):1485-1491
pubmed: 35474099
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1966-1977
pubmed: 31161258
Nat Commun. 2022 Dec 29;13(1):7974
pubmed: 36581633
J Med Chem. 2023 Feb 9;66(3):1712-1724
pubmed: 36256881
Anal Methods. 2023 Jan 19;15(3):377-387
pubmed: 36542448
J Nucl Med. 2022 Oct 20;:
pubmed: 36265911
Bioorg Med Chem. 2022 Nov 1;73:117012
pubmed: 36155319
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295
pubmed: 27573793
EJNMMI Radiopharm Chem. 2022 Jul 19;7(1):18
pubmed: 35852679
Bioconjug Chem. 2022 Jun 15;33(6):1222-1231
pubmed: 35670495
J Nucl Med. 2022 Oct;63(10):1475-1479
pubmed: 35835579
J Nucl Med. 2003 Aug;44(8):1271-81
pubmed: 12902418
Theranostics. 2022 Oct 09;12(16):7067-7079
pubmed: 36276653
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768